ALG treatment of steroid-resistant rejection in patients receiving cyclosporine

Arthur J. Matas, Vavian A. Tellis, Theresa Quinn, Dan Glichlick, Robert Soberman, Robert Weiss, Gattu Karwa, Frank J. Veith

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Thirty-one episodes of biopsy-proved acute rejection (R) in 28 patients maintained on cyclosporine did not respond to high-dose steroids an were treated with antilymphocyte globulin (ALG). Cyclosporine was discontinued in all but three during ALG administration. (A) Twenty-four patients received 26 courses of ALG within 90 days of transplant (11 1st R, 15 2nd or 3rd). Seven treatment courses were cut short due to infection (4), ongoing R (2) and a combination of infection and rejection (1). Only 1 of 7 has a functioning graft. Of the remaining 19 full ALG courses (17 patients) (8 1st R, 11 2nd or 3rd), 13 (11 patients) responded (7 1st R, 6 >1st). The remaining 6 Five patients were treated after 6 months posttransplant; two responded but no grafts currently function. (c) Overall 7 patients developed systemic infection (7 viruses, 1 Candida) with 1 death, and 2 additional patients developed severe thrombocytopenia an leukopenia. Patients responding to their ALG course were restarted on cyclosporine. We conclude that ALG is not as effective I reversing steroid-resistant rejection in patients maintained on cyclosporine. We conclude that ALG is not as effective in reversing steroid-resistant rejection in patients maintained on cyclosporine as it has been in patients maintained on azathioprine. However, more than 50% of steroid-resistant rejection episodes are reversed.

Original languageEnglish (US)
Pages (from-to)579-583
Number of pages5
JournalTransplantation
Volume41
Issue number5
StatePublished - 1986

Fingerprint

Antilymphocyte Serum
Cyclosporine
Steroids
Therapeutics
Transplants
Azathioprine
Leukopenia
Virus Diseases
Infection
Candida
Thrombocytopenia
Biopsy

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Matas, A. J., Tellis, V. A., Quinn, T., Glichlick, D., Soberman, R., Weiss, R., ... Veith, F. J. (1986). ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. Transplantation, 41(5), 579-583.

ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. / Matas, Arthur J.; Tellis, Vavian A.; Quinn, Theresa; Glichlick, Dan; Soberman, Robert; Weiss, Robert; Karwa, Gattu; Veith, Frank J.

In: Transplantation, Vol. 41, No. 5, 1986, p. 579-583.

Research output: Contribution to journalArticle

Matas, AJ, Tellis, VA, Quinn, T, Glichlick, D, Soberman, R, Weiss, R, Karwa, G & Veith, FJ 1986, 'ALG treatment of steroid-resistant rejection in patients receiving cyclosporine', Transplantation, vol. 41, no. 5, pp. 579-583.
Matas AJ, Tellis VA, Quinn T, Glichlick D, Soberman R, Weiss R et al. ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. Transplantation. 1986;41(5):579-583.
Matas, Arthur J. ; Tellis, Vavian A. ; Quinn, Theresa ; Glichlick, Dan ; Soberman, Robert ; Weiss, Robert ; Karwa, Gattu ; Veith, Frank J. / ALG treatment of steroid-resistant rejection in patients receiving cyclosporine. In: Transplantation. 1986 ; Vol. 41, No. 5. pp. 579-583.
@article{027b1a56563d4c94b447aeb6df331204,
title = "ALG treatment of steroid-resistant rejection in patients receiving cyclosporine",
abstract = "Thirty-one episodes of biopsy-proved acute rejection (R) in 28 patients maintained on cyclosporine did not respond to high-dose steroids an were treated with antilymphocyte globulin (ALG). Cyclosporine was discontinued in all but three during ALG administration. (A) Twenty-four patients received 26 courses of ALG within 90 days of transplant (11 1st R, 15 2nd or 3rd). Seven treatment courses were cut short due to infection (4), ongoing R (2) and a combination of infection and rejection (1). Only 1 of 7 has a functioning graft. Of the remaining 19 full ALG courses (17 patients) (8 1st R, 11 2nd or 3rd), 13 (11 patients) responded (7 1st R, 6 >1st). The remaining 6 Five patients were treated after 6 months posttransplant; two responded but no grafts currently function. (c) Overall 7 patients developed systemic infection (7 viruses, 1 Candida) with 1 death, and 2 additional patients developed severe thrombocytopenia an leukopenia. Patients responding to their ALG course were restarted on cyclosporine. We conclude that ALG is not as effective I reversing steroid-resistant rejection in patients maintained on cyclosporine. We conclude that ALG is not as effective in reversing steroid-resistant rejection in patients maintained on cyclosporine as it has been in patients maintained on azathioprine. However, more than 50{\%} of steroid-resistant rejection episodes are reversed.",
author = "Matas, {Arthur J.} and Tellis, {Vavian A.} and Theresa Quinn and Dan Glichlick and Robert Soberman and Robert Weiss and Gattu Karwa and Veith, {Frank J.}",
year = "1986",
language = "English (US)",
volume = "41",
pages = "579--583",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - ALG treatment of steroid-resistant rejection in patients receiving cyclosporine

AU - Matas, Arthur J.

AU - Tellis, Vavian A.

AU - Quinn, Theresa

AU - Glichlick, Dan

AU - Soberman, Robert

AU - Weiss, Robert

AU - Karwa, Gattu

AU - Veith, Frank J.

PY - 1986

Y1 - 1986

N2 - Thirty-one episodes of biopsy-proved acute rejection (R) in 28 patients maintained on cyclosporine did not respond to high-dose steroids an were treated with antilymphocyte globulin (ALG). Cyclosporine was discontinued in all but three during ALG administration. (A) Twenty-four patients received 26 courses of ALG within 90 days of transplant (11 1st R, 15 2nd or 3rd). Seven treatment courses were cut short due to infection (4), ongoing R (2) and a combination of infection and rejection (1). Only 1 of 7 has a functioning graft. Of the remaining 19 full ALG courses (17 patients) (8 1st R, 11 2nd or 3rd), 13 (11 patients) responded (7 1st R, 6 >1st). The remaining 6 Five patients were treated after 6 months posttransplant; two responded but no grafts currently function. (c) Overall 7 patients developed systemic infection (7 viruses, 1 Candida) with 1 death, and 2 additional patients developed severe thrombocytopenia an leukopenia. Patients responding to their ALG course were restarted on cyclosporine. We conclude that ALG is not as effective I reversing steroid-resistant rejection in patients maintained on cyclosporine. We conclude that ALG is not as effective in reversing steroid-resistant rejection in patients maintained on cyclosporine as it has been in patients maintained on azathioprine. However, more than 50% of steroid-resistant rejection episodes are reversed.

AB - Thirty-one episodes of biopsy-proved acute rejection (R) in 28 patients maintained on cyclosporine did not respond to high-dose steroids an were treated with antilymphocyte globulin (ALG). Cyclosporine was discontinued in all but three during ALG administration. (A) Twenty-four patients received 26 courses of ALG within 90 days of transplant (11 1st R, 15 2nd or 3rd). Seven treatment courses were cut short due to infection (4), ongoing R (2) and a combination of infection and rejection (1). Only 1 of 7 has a functioning graft. Of the remaining 19 full ALG courses (17 patients) (8 1st R, 11 2nd or 3rd), 13 (11 patients) responded (7 1st R, 6 >1st). The remaining 6 Five patients were treated after 6 months posttransplant; two responded but no grafts currently function. (c) Overall 7 patients developed systemic infection (7 viruses, 1 Candida) with 1 death, and 2 additional patients developed severe thrombocytopenia an leukopenia. Patients responding to their ALG course were restarted on cyclosporine. We conclude that ALG is not as effective I reversing steroid-resistant rejection in patients maintained on cyclosporine. We conclude that ALG is not as effective in reversing steroid-resistant rejection in patients maintained on cyclosporine as it has been in patients maintained on azathioprine. However, more than 50% of steroid-resistant rejection episodes are reversed.

UR - http://www.scopus.com/inward/record.url?scp=0022511941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022511941&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 579

EP - 583

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -